GILEAD SCIENCES, INC. Repayments of Convertible Debt
GILEAD SCIENCES, INC. (GILD) reported Repayments of Convertible Debt of $426.30 million for the 9-month period ending 2013-09-30, per its 10-Q filed 2013-10-31.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfConvertibleDebt · last filed 2013-10-31
- GILEAD SCIENCES, INC. repayments of convertible debt for the quarter ending 2013-09-30 was $0.00.
- GILEAD SCIENCES, INC. repayments of convertible debt for the quarter ending 2012-09-30 was $0.00.
- GILEAD SCIENCES, INC. repayments of convertible debt for the quarter ending 2011-09-30 was $0.00.
| Period end | Repayments of Convertible Debt 1 month | Repayments of Convertible Debt 3 month | Repayments of Convertible Debt 6 month | Repayments of Convertible Debt 9 month |
|---|---|---|---|---|
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-31 | $426.30M 10-Q · filed 2013-10-31 | ||
| 2013-06-30 | $426.30M 10-Q · filed 2013-08-01 | |||
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $0.00 10-Q · filed 2012-11-06 | ||
| 2012-06-30 | $0.00 10-Q · filed 2012-08-01 | |||
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $649.99M 10-Q · filed 2012-11-06 | ||
| 2011-06-30 | $649.99M 10-Q · filed 2012-08-01 | |||
| 2011-05-31 | $650.00M 10-K · filed 2012-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |